Sato Akinori, Maie Kouichiro, Ohno Yukako, Yoshida Tsuyoshi, Ito Eiichi, Tanabe Yasuhiko, Aizawa Yoshifusa
Department of Cardiology, Niigata Prefectural Shibata Hospital, Niigata, Japan.
Int Heart J. 2011;52(4):243-5. doi: 10.1536/ihj.52.243.
Pulmonary arterial hypertension (PAH) in patients with portal hypertension is also referred to as portopulmonary hypertension (PPHTN). Here, we report a case of PPHTN caused by alcoholic liver cirrhosis in a 43-year-old male who experienced repetitive syncope on exertion. The continuous monitoring of pulmonary artery pressure and radial artery pressure revealed that his PAH was aggravated with a drop in systemic arterial pressure during an exercise test. Bosentan, an endothelin A/B receptor antagonist, improved the patient's hemodynamic parameters and abolished his syncope without adverse effects. This is the first report that bosentan may be effective and safe for PPHTN associated with syncope.
门静脉高压患者的肺动脉高压（PAH）也被称为门肺高压（PPHTN）。在此，我们报告一例43岁男性因酒精性肝硬化导致的PPHTN病例，该患者在运动时反复出现晕厥。对肺动脉压和桡动脉压的持续监测显示，在运动试验期间，他的PAH随着体循环动脉压下降而加重。波生坦，一种内皮素A/B受体拮抗剂，改善了患者的血流动力学参数并消除了他的晕厥，且无不良反应。这是关于波生坦可能对伴有晕厥的PPHTN有效且安全的首例报告。
